- EsoCap’s targeted application technology drastically increases mucosal contact time and enables effective local treatment of various esophageal diseases for the first time
- Proof of principle in human established; Phase II trial underway
- Strong IP granted and Orphan Drug Designation approved in lead indication
- Partnerships up and running
EsoCap AG, the Swiss biotech company dedicated to improving the lives of patients with serious diseases of the upper gastrointestinal tract, owns and develops the worldwide first local Esophagus therapy. Effective topical treatment of the esophagus is extremely difficult to achieve due to the ultra-short drug contact time of one to two seconds from the mouth to the stomach with the currently available drug formulations. While a study demonstrates that prolonged mucosal contact time results in better drug efficacy[1], even the passing time of orodispersible tablets from mouth to stomach is less than one minute[2], too little time for drug substances to stick to their designated application site, the esophagus, and unravel their full potential.
[1] Dellon et al., 2012. Viscous Topical Is More Effective Than Nebulized Steroid Therapy for Patients With Eosinophilic Esophagitis. Gastroenterology, 143 (2):321-324.
[2] Burton et al., 1995. Intragastric Distribution of Ion-exchange Resins: a Drug Delivery System for the Topical Treatment of the Gastric Mucosa. J. of Pharmacy and Pharmacology, 47: 901-906
